



(43) International Publication Date
23 December 2015 (23.12.2015)

(10) International Publication Number
WO 2015/193380 A2

- (51) **International Patent Classification:**
A61K 9/107 (2006.01)
- (21) **International Application Number:**
PCT/EP2015/063606
- (22) **International Filing Date:**
17 June 2015 (17.06.2015)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
14173067.1 19 June 2014 (19.06.2014) EP
- (71) **Applicant:** SOLURAL PHARMA APS [DK/DK]; Ener-
givej 42, DK-2750 Ballerup (DK).
- (72) **Inventor:** HØJGAARD, Bent; Morelvænget 5, DK-3450
Allerød (DK).
- (74) **Agent:** LBKPATENT APS; Cobis Ole Maaløes Vej 3,
2200 Copenhagen (DK).
- (81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*



WO 2015/193380 A2

(54) **Title:** SOLID ORAL DOSAGE FORM OF LIPOPHILIC COMPOUNDS

(57) **Abstract:** The present invention relates to a pharmaceutical composition comprising compound having a log P of at least 5 and a vehicle, wherein the vehicle comprises (a) a fat component in an amount sufficient to achieve lymphatic absorption in a mammal, wherein the fat component is selected from a mono-glyceride of long chain fatty acids, a tri-glyceride of long chain fatty acids, and a mono- and tri-glyceride of long chain fatty acids.